Table 2.
Participant and sample characteristics.
| Characteristics | Participants n = 109 |
Samples n = 269 |
|---|---|---|
| Demographics | ||
| age, mean (SD; range) | 61.2 (16.5; 22.0–86.0) | 60.8 (15.8; 22.0–86.0) |
| female, n (%) | 78 (71.6) | 191 (71.0) |
| BMI, mean, (SD; range) | 26.0 (4.1; 18.0–37.2) | 26.0 (3.9; 18.0–37.2) |
| NIP | 44 (40.4) | 84 (31.2) |
| MTX-treated patients | 65 (59.6) | 185 (68.8) |
| Rheumatoid arthritis, n (%) | 44 (67.7) | 122 (65.9) |
| Psoriatic arthritis, n (%) | 10 (15.4) | 30 (16.2) |
| other diagnosis, n (%) | 11 (16.9) | 33 (17.8) |
| MTX monotherapy, n (%) | 15 (23.1) | 43 (23.2) |
| MTX in combination therapy, n (%) | 50 (76.9) | 142 (76.8) |
| Before booster, n (%) | 60 (55.0) | 83 (30.9) |
| After first booster, n (%) | 109 (100.0) | 186 (69.1) |
| Vaccines used for basic immunization* | ||
| 2x BNT162b2, n (%) | 94 (86.2) | 65 (78.3) |
| 2x mRNA-1273, n (%) | 8 (7.3) | 11 (13.3) |
| 2x AZD1222, n (%) | 4 (3.7) | 2 (2.4) |
| 1x AZD1222 + 1x mRNA, n (%) | 3 (2.8) | 5 (6.0) |
| Vaccines used for booster** | ||
| BNT162b2, n (%) | 95 (87.2) | 160 (86.0) |
| mRNA-1273, n (%) | 14 (12.8) | 26 (14.0) |
BMI, body mass index; MTX, methotrexate; NIP, non-immunosuppressed persons; *sample characteristics are given for samples taken before booster; **sample characteristics are given for samples taken after booster.